Semathera Inc
SemaThera is a spin-off company from AmorChem Fund 1, which focuses on a novel target, semaphorin 3A (SEMA3A). The Company is currently developing bispecific SEMA3A / VEGF inhibitors (traps) to prevent vascular leakage and damper the inflammation in diabetic macular edema (DME). The technology targets the 30% DME patients who are poor responders to current anti-VEGF therapies.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
5
1 to 10 range
Open roles
—
no listings
Distinct roles
3
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Semathera Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
- MB
Michelle Barbagallo
Scientist · Science
EmailPhone - CH
Cara Hawey
Scientist · Science
EmailPhone - GC
Garth Cumberlidge
President, Director & Chief Executive Officer · Other
EmailPhone - MS
Mike Sapieha
É É · Other
EmailPhone
Showing 4 of 4 verified contacts
Top roles at Semathera Inc
3 distinct titles indexed · top 3 shown.
- 2scientist
- 1president, director & chief executive officer
- 1é é
Sign up to unlock all 4 contacts at Semathera Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Semathera Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.